Carolyn Leveret
Principal Scientist, Oncology Medicinal Chemistry
Pfizer Inc.
Macedonia
Biography
Carolyn Leverett, PhD, is a Principal Scientist in Oncology Medicinal Chemistry. Since joining Pfizer in 2012, she has been involved in the development of a variety of microtubule inhibitor-based payloads for use as an antibody-drug conjugate towards the treatment of cancer. This work has resulted in several publications, including a recent report in ACS Medicinal Chemistry Letters (ACS Medicinal Chemistry. Lett. 2016, 7, 999) describing the SAR and synthesis of a number of tubulysin payloads, natural-product based cytotoxic agents which have shown to be potent against a variety of cancer cell lines. Carolyn Leverett, PhD, is a Principal Scientist in Oncology Medicinal Chemistry. Since joining Pfizer in 2012, she has been involved in the development of a variety of microtubule inhibitor-based payloads for use as an antibody-drug conjugate towards the treatment of cancer. This work has resulted in several publications, including a recent report in ACS Medicinal Chemistry Letters (ACS Medicinal Chemistry. Lett. 2016, 7, 999) describing the SAR and synthesis of a number of tubulysin payloads, natural-product based cytotoxic agents which have shown to be potent against a variety of cancer cell lines.
Research Interest
Principal Scientist, Oncology Medicinal Chemistry
